Kopran Limited has announced that its Board of Directors has reaffirmed the merger plan with Kopran Laboratories Limited, a promoter group company, following a comprehensive review of updated documentation and financials.

Key Highlights of the Board Decision

• The Board meeting, held on August 8, addressed previous regulatory observations from BSE and NSE regarding delayed filings and the need for fresh board approval with updated financials.
• After careful consideration, the Board concluded that no changes are required to the original scheme approved on March 20.
• The swap ratio for the merger remains unchanged from the initial announcement.

Updated Documentation and Reports

The Board's decision was based on a thorough examination of fresh documentation, including:

1. A valuation report dated August 7, issued by Ernst & Young Merchant Banking Services LLP.
2. A fairness opinion dated August 8, provided by Saffron Capital Advisors Pvt Limited.
3. An auditor's certificate dated August 6, from the company's statutory auditors, Khandelwal Jain & Co., confirming compliance with applicable Accounting Standards.

Financial Considerations

The Board reviewed the following financial information:

• Audited financials for the three preceding financial years for both companies.
• Audited financial results with the Audit report for Q1 for Kopran Laboratories Limited.
• Unaudited standalone and consolidated financial results with Limited Review report for Q1 for Kopran Limited.

Merger Structure

• Kopran Laboratories Limited will be the transferor company, merging with Kopran Limited as the transferee company.
• The merger is structured as a Scheme of Amalgamation Merger by Absorption.

Regulatory Compliance

The company has emphasized its commitment to regulatory compliance, addressing the observations made by BSE and NSE. The reaffirmation of the merger plan with updated documentation demonstrates Kopran Limited's dedication to transparency and adherence to regulatory requirements.

Looking Ahead

With the Board's reaffirmation, Kopran Limited is poised to move forward with the merger process. Shareholders and market observers will likely be watching closely for further developments and the potential impact on the company's operations and market position.

The Board meeting, which commenced at 12:30 PM and concluded at 1:45 PM on August 8, marks a significant step in Kopran Limited's corporate strategy, reinforcing its commitment to the previously announced merger plan.

Kopran Ltd , a prominent player in the pharmaceutical industry, has released its unaudited financial results for the first quarter, along with significant changes to its leadership structure.

Financial Performance

For the quarter ended June 30, Kopran Ltd reported consolidated revenue from operations of Rs 135.22 crore, compared to Rs 139.44 crore in the same quarter of the previous year, representing a slight decrease of 3.00%. The company's consolidated profit for the quarter stood at Rs 7.45 crore, down from Rs 11.10 crore in the corresponding quarter of the previous year, marking a 32.88% decline.

Key Financial Metrics

Leadership Changes

The Board of Directors has approved several significant leadership changes:

1. New Independent Director: Mr. Chandresh Gunvant Gandhi has been appointed as an Additional Independent Director for a five-year term, from July 29, 2025, to July 28, 2030, subject to shareholder approval.

2. Chairman & Managing Director: Mr. Surendra Somani, currently serving as Executive Vice-chairman, will be appointed as Chairman & Managing Director for a three-year term from January 1, 2026, to December 31, 2028, subject to shareholder approval.

3. Resignation: Mr. Susheel Somani has resigned as Non-Executive Director due to continued ill health, effective July 29, 2025.

Other Key Developments

• The company has appointed M/s Smita Prabhu & Associates as Secretarial Auditor for five years, from FY 2025-26 to FY 2029-30, subject to shareholder approval.

• Kopran Ltd's 66th Annual General Meeting is scheduled for September 11, 2025, to be held through video conferencing.

Management Commentary

While specific management comments were not provided in the available data, the leadership changes and financial results indicate that Kopran Ltd is positioning itself for future growth and adapting to market challenges.

The appointment of Mr. Chandresh Gunvant Gandhi, a Chartered Accountant with over 30 years of professional experience, as an Independent Director, suggests a focus on strengthening financial oversight and corporate governance.

The transition of Mr. Surendra Somani to the role of Chairman & Managing Director, leveraging his four decades of experience in the pharmaceutical industry, signals continuity in leadership while potentially bringing new strategic direction to the company.

As Kopran Ltd navigates through a challenging quarter with decreased revenue and profit, these leadership changes may play a crucial role in steering the company towards improved performance in the coming quarters.